Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company centered on nitric oxide (NO) technologies, and its news flow reflects both commercial execution and clinical development. Company announcements frequently highlight progress with the LungFit PH system, a cylinder-free NO generator and delivery device approved for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Investors can follow updates on U.S. hospital adoption, international distribution agreements, regulatory milestones, and quality certifications related to this platform.
News items also cover Beyond Air’s broader LungFit pipeline, including clinical trials evaluating higher-concentration NO for severe lung infections such as viral community-acquired pneumonia and nontuberculous mycobacteria. These stories often discuss regulatory submissions, design patents for next-generation devices, and participation in medical and industry conferences.
On the biopharmaceutical side, Beyond Air and its affiliates generate news about oncology and neurology programs. Beyond Cancer, Ltd. reports early-stage clinical data and preclinical work using ultra-high concentration NO for solid tumors, while NeuroNOS communications describe small-molecule nNOS inhibitors, preclinical findings in Autism Spectrum Disorder and brain cancers, and U.S. FDA Orphan Drug Designations for glioblastoma and Phelan-McDermid Syndrome. Transactions such as the agreement for XTL Biopharmaceuticals to acquire a majority stake in NeuroNOS are also covered.
Capital markets and corporate governance updates are another recurring theme, including private placements, warrant exercises, promissory notes, equity purchase agreements, reverse stock splits, and leadership changes. For investors and analysts tracking XAIR, this news page provides a centralized view of commercial rollouts, clinical milestones, financing activity, and strategic partnerships that shape the company’s nitric oxide-focused portfolio.
Beyond Cancer, Ltd., an affiliate of Beyond Air (NASDAQ: XAIR), has entered a sponsored research agreement with Stanford School of Medicine to advance its ultra-high concentration nitric oxide (UNO) therapy for solid tumors. Dr. Frederick M. Dirbas and Dr. Mark D. Pegram have been appointed to the Scientific Advisory Board (SAB), with Dirbas serving as Chair. This collaboration aims to influence clinical development and regulatory submissions for UNO therapy, which is being studied for its potential to enhance cancer treatment efficacy and safety. The first human study for UNO is underway, focusing on solid tumors.
Beyond Air, a medical device and biopharmaceutical company, will report its financial results for the third fiscal quarter ending December 31, 2022, on February 9, 2023. The announcement comes as the company focuses on developing inhaled nitric oxide for treating respiratory conditions and ultra-high concentration nitric oxide for solid tumors through its affiliate, Beyond Cancer. A conference call will be held at 4:30 PM ET the same day to discuss these results. Beyond Air has received FDA approval for its LungFit PH system, targeting persistent pulmonary hypertension of the newborn, and is advancing other clinical trials.
Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), published pre-clinical data showing that ultra-high concentrations of nitric oxide (UNO) significantly enhance immune responses against solid tumors. The study indicated that UNO-treated mice exhibited improved survival rates and reduced tumor metastasis. These findings were detailed in the journal Cancer Cell International. The research supports the potential of UNO as an innovative treatment for solid tumors, with a first-in-human Phase 1 trial already in progress.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Steve Lisi, its Chairman and CEO, will present at the Piper 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York, NY. Lisi's presentation is scheduled for November 30, 2022, from 1:10 – 1:30 PM ET. Beyond Air specializes in developing inhaled nitric oxide for respiratory conditions and ultra-high concentration nitric oxide for solid tumors. The company has FDA approval for its LungFit PH system aimed at treating persistent pulmonary hypertension in newborns.
Beyond Cancer, Ltd., a subsidiary of Beyond Air (NASDAQ: XAIR), announced promising in vivo data demonstrating that their ultra-high concentration nitric oxide (UNO) therapy combined with anti-PD-1 treatment significantly improves tumor regression rates and survival in CT26 tumor-bearing mice. This data, presented at the 37th Annual SITC Meeting in Boston, highlights the potential of UNO therapy not only to treat primary tumors but also to address metastatic disease effectively. The findings suggest a strong rationale for further advancing clinical studies in combination with immune checkpoint therapies.
Beyond Air reported its financial results for the fiscal quarter ending September 30, 2022, highlighting a net loss of $12.8 million, or ($0.40) per share. This marks an increase in loss compared to $8.7 million, or ($0.36) per share, in the same quarter last year. R&D expenses rose to $4.5 million, up from $2.8 million, driven by spending on ultra-high concentration nitric oxide (UNO). Despite a total cash burn of $10.4 million, the company has $72.5 million in cash and securities. Beyond Air is advancing its LungFit PH commercial launch and plans further studies in various respiratory conditions.
Beyond Air, Inc. (NASDAQ: XAIR) announced positive results from its LungFit PRO pilot study for treating Viral Community-Acquired Pneumonia (VCAP) with inhaled nitric oxide (NO). The study demonstrated a statistically significant reduction in the duration of oxygen support for patients treated with 150 ppm NO compared to standard supportive treatment. Safety data indicated no treatment-related adverse events. These findings support the efficacy and safety of high-concentration NO in pneumonia treatment, particularly for COVID-19 patients, and highlight Beyond Air's commitment to advancing this therapy.
Beyond Air (NASDAQ: XAIR) will report its second fiscal quarter financial results for the period ending September 30, 2022, on November 8, 2022, at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for respiratory conditions and has received FDA approval for its LungFit PH system. This conference call will provide insights into the company’s financial performance and future developments.
Beyond Air (NASDAQ: XAIR) announced positive results from its pilot study of the LungFit GO device for treating severe nontuberculous mycobacteria (NTM) lung disease. Conducted with 15 patients, the study demonstrated favorable safety and efficacy, with no dose reductions required during at-home use. Patients maintained high compliance (>90%) and experienced improvements in quality of life. No serious adverse events were reported, and trends indicated a reduction in bacterial load. This study supports the development of intermittent high-dose nitric oxide therapy for NTM.
Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), announced it will present significant data on its ultra-high concentration nitric oxide (UNO) therapy during the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 8-12, 2022. The presentation, titled Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice, will take place on November 10, 2022. UNO therapy aims to prevent relapse or metastatic disease in solid tumors and shows potential for minimal toxicity.